IA
VNDA icon

IFP Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

IFP Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-700
Closed -$16K – 3878
2018
Q3 		$16K Buy
+700
New +$14.3K ﹤0.01% 2594

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's VNDA Position: Q2 2026 in Review

IFP Advisors increased its Vanda Pharmaceuticals (VNDA) stake by 934% in Q2 2026, buying an estimated $15K and bringing the position to 2,543 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3130.

IFP Advisors first reported a position in VNDA in Q3 2017 and has held it in 21 quarters since. The position peaked at $37K in Q4 2018. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • IFP Advisors held 2,543 shares of Vanda Pharmaceuticals worth $15.6K as of Q2 2026.
  • IFP Advisors bought 2,297 Vanda Pharmaceuticals shares in Q2 2026, an estimated $15K.
  • Vanda Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3130 holding.
  • IFP Advisors first reported a position in Vanda Pharmaceuticals in Q3 2017 and has held it in 21 quarters since.
  • IFP Advisors's Vanda Pharmaceuticals position peaked at $37K in Q4 2018.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.